^
    2d
    Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=78, Recruiting, City of Hope Medical Center | Active, not recruiting --> Recruiting | N=38 --> 78
    Enrollment open • Enrollment change
    |
    Imfinzi (durvalumab) • lenalidomide
    3d
    Adulthood diagnosis of Nijmegen breakage syndrome in twins with antibody deficiency clinical presentation. (PubMed, Clin Immunol)
    These findings expand the genotypic spectrum of NBS and demonstrate that compound heterozygosity for non-classical NBN variants can lead to an adult identification of the disease. These cases highlight the importance of integrating genetic and functional analyses to facilitate the recognition of DNA repair disorders beyond childhood and to guide appropriate clinical surveillance and management.
    Journal
    |
    NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin))
    6d
    RV-CL-PTCL-PI-003974: Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma (clinicaltrials.gov)
    P2, N=30, Completed, Northwestern University | Active, not recruiting --> Completed
    Trial completion
    |
    ALK negative
    |
    lenalidomide • romidepsin
    7d
    Case Report: Cutaneous niche-restricted malignant phenotypes in PTCL-NOS revealed by single-cell sequencing. (PubMed, Front Oncol)
    Despite CHOP, CHOEP, DA-EPOCH, and AC-CHOP (azacitidine plus chidamide) regimens, the patient experienced primary refractory disease and died 6 months from diagnosis following COVID-19 superinfection. To our knowledge, this is the first case reporting single-cell transcriptomic comparison of skin versus blood compartments in PTCL-NOS, revealing how cutaneous microenvironment sculpts aggressive malignant phenotypes and providing potential targets for compartment-specific therapy.
    Journal
    |
    IL17A (Interleukin 17A)
    |
    azacitidine • Epidaza (chidamide)
    7d
    Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns. (PubMed, Haematologica)
    These findings show improved outcomes in early stage nodal T-cell lymphomas compared to historical data for allcomers. In addition, favorable outcomes in stage I disease treated with chemoradiation support such strategy as an excellent treatment option in this setting.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK negative
    9d
    TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma (clinicaltrials.gov)
    P3, N=180, Not yet recruiting, Tarapeutics Science Inc.
    New P3 trial
    13d
    Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas (clinicaltrials.gov)
    P1, N=20, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: Apr 2026 --> Dec 2025
    Enrollment open • Trial initiation date
    |
    doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    14d
    Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma (clinicaltrials.gov)
    P2, N=330, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Oct 2026 --> Jun 2027
    Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    ALK positive
    |
    Jakafi (ruxolitinib) • cyclophosphamide • sirolimus
    14d
    KILT: Study of Lacutamab in Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P2, N=49, Active, not recruiting, The Lymphoma Academic Research Organisation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2)
    |
    gemcitabine • lacutamab (IPH4102)
    14d
    Immune checkpoint therapy in pediatric and adolescent lymphomas. (PubMed, Haematologica)
    In PMBCL, the Children's Oncology Group (COG) and the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) recently completed a randomized phase III trial of nivolumab in combination with chemo-immunotherapy in children and adults with newly diagnosed PMBCL...In ALCL and ANKL, ongoing clinical trials are evaluating the efficacy of ICT. Given the transformational role of ICT for pediatric Hodgkin lymphoma, there is significant promise for the use of ICT in multiple subtypes of pediatric non-Hodgkin lymphoma with increased expression of PD-L1.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab)
    15d
    Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
    New trial
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin)
    16d
    Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas (clinicaltrials.gov)
    P2, N=25, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD4 (CD4 Molecule)
    |
    Copiktra (duvelisib) • ETP-47187